comprehensive -WSS

comprehensive

author：explore 2025-08-28 08:40:35 - browse：3

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Boston Scientific acquires urology company Axonics for $3.7 billion

WSS

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Paxlovid study fails to answer questions over benefit for broader groups

#NeedHerScience: shining a light on gender disparities in medicine

Allen Institute goes after foundational questions, CEO Costa says

The battle over the Brookhaven Landfill on Long Island

Boston Scientific acquires urology company Axonics for $3.7 billion

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Arena BioWorks launches in Cambridge to speed drug discovery

Activists slam private health insurers over coverage restrictions

Colonoscopy at 40? Study finds a possible benefit

Affirmative action in medical school literally saved lives

American taxpayers paid $1.8 trillion in health care costs in 2022

Cancer drug shortages should be causing more outrage

#NeedHerScience: shining a light on gender disparities in medicine

At least 13 dead in Texas as scorching temps continue

WATCH: Why do fingernails fall off when they're damaged?

entertainment

The strategy behind pharma's lawsuits over drug pricing reform

With FDA staff opposed to Sarepta therapy, top official intervened

New guidelines on severe brain injury complicate already difficult decisions

Hospital chaplains balance Covid safety with patients’ spiritual needs

Merck to acquire Harpoon Therapeutics for $680 million

Stories you might have missed in 2023: health, science, medicine

entertainment

hotspot

entertainment

hotspot